Accessibility StatementSkip Navigation IRVING, Texas, Nov. 17, 2025 /PRNewswire/ -- Caris Life Sciences®Â (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company will attend the following investor conferences: Contact [email protected] to schedule meetings. About Caris Life SciencesCaris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is acti ...

Core Insights - Caris Life Sciences has identified TET2 clonal hematopoiesis (CH) as a promising biomarker for improved response to immune checkpoint inhibitor (ICI) therapy in patients with solid tumors [1][3] - The study, led by Dr. Padmanee Sharma, utilized TET2-mutant laboratory models to explore how these mutations influence immune dynamics within the tumor microenvironment [2] - The research analyzed outcomes from nearly 36,000 non-small cell lung cancer (NSCLC) patients and over 25,000 colorectal cancer (CRC) patients, providing substantial evidence supporting TET2-CH as a potential biomarker for enhanced ICI response [3] Company Overview - Caris Life Sciences is a leading AI TechBio company focused on precision medicine, developing innovative solutions to transform healthcare through comprehensive molecular profiling and advanced AI applications [6] - The company has created a large-scale, multimodal clinico-genomic database to analyze the molecular complexity of diseases, enhancing early detection, diagnosis, monitoring, therapy selection, and drug development [6][7] - Caris operates internationally with offices in multiple locations, including the U.S., Japan, and Switzerland, and aims to realize the potential of precision medicine to improve human health [7]

Core Insights - Caris Life Sciences will present six studies at the ESMO Congress 2025, showcasing the impact of multiomics in precision medicine and cancer treatment [1][2][3] Research Highlights - The studies involve collaboration with over 25 leading cancer centers globally, emphasizing Caris' leadership in next-generation sequencing and biomarker discovery [2][7] - Tumor types covered include colorectal, gastric, breast, pancreatic, head & neck, prostate, urothelial, renal, and biliary tract cancers [2] Presentation Formats - The research will be presented in various formats: one oral "Proffered Paper," one mini-oral, and four poster presentations [2] - Key presentations include topics on Mismatch Repair Deficiency and its implications for immune checkpoint blockade [3][4] Company Overview - Caris Life Sciences is a pioneer in precision medicine, utilizing advanced AI and machine learning to enhance molecular profiling and cancer treatment [9][10] - The company aims to improve clinical outcomes through innovative research and collaboration within the Caris Precision Oncology Alliance, which includes 97 cancer centers [7]

Company Overview - Caris Life Sciences is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer [2] - The company is headquartered in Irving, Texas, with additional offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan, and Basel, Switzerland [3] - Caris provides services in the U.S. and other international markets through its own operations and distributor partners [3] Financial Reporting - Caris Life Sciences will report its second quarter 2025 financial results on August 12, 2025 [1] - A conference call and live webcast will be held at 3:30 p.m. CT (4:30 p.m. ET) to discuss these financial results [1] - A replay of the webcast will be available shortly after the call on the Investor Relations section of the Caris Life Sciences website [1] Technological Capabilities - The company utilizes comprehensive molecular profiling, including Whole Exome and Whole Transcriptome Sequencing, combined with advanced AI and machine learning algorithms [2] - Caris has developed a large-scale, multimodal clinico-genomic database and computing capability to analyze the molecular complexity of diseases [2] - This integration of next-generation sequencing, AI, machine learning technologies, and high-performance computing enables the development of advanced precision medicine diagnostic solutions [2]